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Abstract
Understanding the pathogenesis in the early stages of late-onset Alzheimer’s disease
(AD) can help in gaining important mechanistic insights into this devastating neurode-
generative disorder. Integration of multiple computational approaches to address the
different levels of information embedded in microarray data, such as networks of co-
expressed genes, functional annotation modules, and cis-regulatory elements shared by
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co-expressed genes, leads to greater understanding of complex diseases such as AD. We
use our recently developed methods for co-expression network analysis (CoExp) and
genome-wide motif identification (WordSpy) along with functional annotation cluster-
ing on single cell expression data to analyse AD. CoExp automatically identified 6 clus-
ters/modules, each of which represented a biological process perturbed in AD. Inter-
estingly, AD related genes like APOE, A2M, PON2, MAP4 and cardiovascular diseases
(CVD) associated genes such as COMT, CBS, WNK1 all congregated in one of the six
modules. This module that contained 18 disease associated (cardiovascular, neurodegen-
eration, diabetes, stroke) genes had the maximum number of hub genes. Some of the
disease related genes were also hub genes while many of them were directly connected to
one or more hub genes. Further investigation of this disease associated module unveiled
significant cis-regulatory elements that were significantly similar to the binding sites of
transcription factors involved in AD and CVD. Our results showcase extensive links be-
tween genes associated with AD and CVD at the co-expression and co-regulation levels
and provide strong supporting evidence to the hypotheses linking CVD and AD.
1 Introduction
Late-onset Alzheimer’s disease (AD) is a complex progressive neurodegenerative disorder of the
brain and is the commonest form of dementia. A systems biology approach is an efficient way
to analyse complex diseases, such as AD, that are polygenic and have multiple, interacting genes
contributing to the spectrum of variation.
We perform a transcriptome-based analysis of AD by combining our newly developed co-
expression network (CoExp) and genome-wide motif identification (WordSpy) methods to study
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Single cell microarray expression data
Use SAM to identify statistically significant differentially expressed genes 
Build gene co-expression networks
Identify dense networks / modules
Identify hub genes
Use EASE to identify 
enriched GO categories
Co-expression network tool
WordSpy
Identify enriched cis-regulatory elements 
in clusters with AD enriched genes
Check for clusters enriched with genes linked to
Alzheimer’s disease
Figure 1: Sequence of steps taken to analyse incipient Alzheimer’s disease (AD) from single cell expression
data. We apply co-expression network analysis and WordSpy (motif finding) in an integrated manner to
study AD and reveal connections to other conditions such as cardiovascular diseases and diabetes.
early response genes in AD(Ruan and Zhang, 2006b, 2008; Wang and Zhang, 2006). In the first
stage, CoExp is used to construct modules of tightly correlated genes (i.e. high similarity in their
expression profiles). In the next stage, WordSpy identifies regulatory cis-elements (motifs), which
are then used to group genes within a module based on the motifs they share. The analysis follows
the procedure shown in Figure 1.
The present work unveiled 1663 genes that are differentially expressed in AD. CoExp was ap-
plied to these genes resulting in 6 modules of co-expressed genes, each module representing key
biological processes perturbed in AD. Within the 6 modules we identified 107 highly connected
(‘hub’) genes, many of which play important roles in AD. Functional annotation clustering based
on association to human diseases resulted in the identification of 18 disease related (cardiovascu-
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lar diseases, AD/neurodegenerative diseases, stroke and diabetes) transcripts aggregating in one
module (referred to as the disease associated module). Some of these 18 genes were also hub
genes, while many of them were directly connected to one or more hub genes. Further analysis
of the disease associated module using WordSpy1, resulted in several cis-regulatory elements that
matched binding sites of transcription factors involved in diseases that are known to co-occur with
AD. The final result is a set of co-expressed and co-regulated modules describing the higher level
characteristics linking AD and cardiovascular diseases.
Our work is significantly different from that by Miller et al.(Miller et al., 2008) as we use a
different co-expression network building method (CoExp) to generate modules of co-expressed
genes and then identify cis-regulatory motifs in a module. CoExp is a spectral algorithm that was
designed to optimise a modularity function and automatically identify the appropriate number of
modules(Ruan and Zhang, 2006b, 2008). The cis-regulatory elements discovered in the promoter
regions of disease related genes provide further insights into the possible transcriptional regulation
of the genes involved in AD and their connection to other diseases, such as cardiovascular diseases,
stroke and diabetes. Moreover, the single cell dataset, which is less noisy compared to mixed cell
microarray data, is more recent(Dunckley et al., 2006) compared to those analysed by Miller et
al. Most importantly, unlike multiple studies comparing AD and ageing(Ricciarelli et al., 2004;
Miller et al., 2008; Pereira et al., 2007), to the best of our knowledge, our study is the first that
has identified links between cardiovascular diseases, AD/neurodegenerative diseases and diabetes
using a transcriptome-based systems biology approach. Lastly, the AD expression data that we
analyse are from the entorhinal cortex, a region of the brain known to be the germinal site of AD.
Despite the differences between our study and that by Miller et al., we have established interesting
1CoExp and WordSpy can be retrieved from http://www.cse.wustl.edu/ ∼zhang/
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links between the two studies, thereby highlighting the commonalities between AD, ageing, and
cardiovascular diseases. We believe that analyses such as ours and that by Miller et al. are the
pieces of a puzzle that will result in a more comprehensive understanding of complex diseases
such as Alzheimer’s and its link to other conditions/diseases.
2 Data and Methods
2.1 Data
Pathologically AD is characterised by the presence of neurofibrillary tangles (NFT) in the neurons
of the entorhinal cortex and hippocampus. Dunckley et al. dataset consists of 13 normal controls
(Braak stages 0–II; average age: 80.1 years) and 20 AD affected (Braak stages III–IV; average
age: 84.7 years) samples obtained by laser capture microdissection (LCM) from the entorhinal
cortex(Dunckley et al., 2006). Braak stages III–IV is considered ‘incipient’ AD(Rossler et al.,
2002; Braak and Braak, 1991). In this dataset, 1000 neurons were collected from each of the 33
samples via LCM.
Data were normalised using gcRMA(Irizarry et al., 2006). Probesets were mapped to genes
using DAVID(Dennis et al., 2003). Probesets that did not map to any gene name and those match-
ing to hypothetical proteins with no known functions, at the time of writing this manuscript, were
removed. When multiple probesets mapped to the same gene, only the probeset with the highest
mean was selected. Differentially expressed genes were selected using significance analysis of
microarrays (SAM)(Tusher et al., 2001).
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2.2 Construction of co-expression networks
We use a network-based approach to identify modular structures/clusters embedded in microarray
gene expression data. The co-expression network (CoExp) method constructs co-expression net-
works from microarray data and then uses a spectral based clustering method to identify subgraphs
within the network(Ruan and Zhang, 2006b, 2008). Each node in the network is a gene and edges
represent expression similarities between genes. The idea is that genes involved in the same func-
tional pathway are directly connected to each other or linked via short paths. After the network is
created, the nodes are clustered into different dense subgraphs. Most clustering algorithms require
the user to specify the number of clusters/modules. However, CoExp uses a spectral based cluster-
ing algorithm that optimises the modular function proposed by Newman and Girvan(Newman and
Girvan, 2004) to automatically determine the appropriate number of modules(Ruan and Zhang,
2006b, 2008). The CoExp is easily scalable to large networks. Further evidence of its robustness
can be found in (Ruan and Zhang, 2008, 2006a).
EASE (http://niaid.abcc.ncifcrf.gov/home.jsp) was used to identify overrepresented biological
processes in each module as well as perform functional annotation clustering based on association
to human diseases.
2.3 Identification of regulatory cis-elements
The interaction of transcription factors (TFs) and cis-acting DNA elements determines the gene
activity under various environmental conditions. Identifying functional TF binding sites, however,
is not trivial, since TF binding sites are usually short and degenerate, and are often located several
hundred to thousand bases upstream to the translational starting sites. Here we combine several
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data sets and a whole-genome analysis method to discover short DNA sequence motifs that are sta-
tistically enriched in the promoters of genes in the same co-expression module and are associated
with gene co-expression.
Briefly, we first download the promoter sequences for human ORFs from the DBTSS database
(Wakaguri et al., 2008). Each promoter includes 1000bp upstream and 200bp downstream se-
quences relative to the transcription starting site, defined from full length cDNA data. From this
data set we extract n sets of promoter sequences (referred to as experimental sets), where n is
the number of co-expression modules. The i-th experimental set contains the promoter sequences
of genes in the i-th co-expression module. The complete set of human gene promoters is used
as the background set. We then run WordSpy, a steganalysis-based genome-wide motif-finding
method(Wang and Zhang, 2006), on each experimental set in order to discover statistically sig-
nificant k-mers (motifs) (for k = 6, 7, 8, 9, 10) according to a generative model of the promoter
sequences.
Each k-mer identified by WordSpy is then subject to two filtering steps. In the first filtering
step, we select motifs that are specifically enriched in the experimental set. We count the number
of instances that a k-mer appears in the experimental set (denoted by x) and in the background set
(denoted by b). Then we compute the probability that we would expect by chance at least the same
number of occurrences in the experimental set given the number of occurrences in the background
set. This probability is computed using the cumulative hyper-geometric distribution as follows -
P (x, b,Ni, N) =
min{x,b}∑
k=x
(Nik )(
N−Ni
b−k )
(Nx )
(1)
where Ni and N are the sizes of the i-th experimental set and the background set, respectively. We
filter out the k-mers that have a p-value ≥ 0.01.
7
The second filter is used to select motifs that are associated with strong and significant co-
expression patterns. For each motif remaining after the first filtering phase, we obtain a set of genes
(‘target set’) in which each gene in this set contains the motif in its promoter region. We compute
the average pair-wise Pearson correlation coefficients, denoted by pcc, from the expression profiles
of the genes in the target set. Furthermore, we randomly sample 100 control sets of genes from the
background set that have the same size (i.e. number of genes) as the target set, and compute the
pcc of each control set. The mean and standard deviation (denoted by mpcc and spcc, respectively)
of the pcc values for the control sets are then used to compute the Z-score of the pcc value for the
target set as follows -
Zscore =
(pcc−mpcc)
spcc
(2)
A motif is retained only if its pcc > 0.4, and its Z-score > 2.
Finally, the motifs that have passed both filters are compared to the known TFBS in the JASPAR
database(Sandelin et al., 2004). We pre-filter the TFBSs in the databse that have information
content ≤ 6 bits, since these TFBSs are short and have high degeneracy and, hence, may match
to some known motifs by chance. Then we compute the best un-gapped alignment between the
motifs (n-mers) and the known binding sites (position specific weight matrices) using a metric
called the information score, which is the same metric used in the Matlnspector program(Quandt
et al., 1995) included in the TRANSFAC suite. We consider a motif match to a known TFBS if the
information score is ≥ 0.8.
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3 Results and Discussion
SAM identified 1663 differentially expressed (DE) genes between AD samples and controls at a
false discovery rate (FDR) of 0.11%(Tusher et al., 2001). All the enriched biological processes of
the transcripts is shown in Table S1 in the supplemental data files. Many of the processes known
to be affected in Alzheimer’s are enriched in the list of 1663 transcripts.
3.1 Modular organisation of significant genes via co-expression networks
The co-expression network method (CoExp) was applied to the set of 1663 genes and resulted in
6 modules(Ruan and Zhang, 2006b, 2008). Figure 2 shows the resulting adjacency matrix and
Figure 3 shows the co-expression network.
The two disconnected groups of modules in Figure 3 represent 2 groups of anti-correlated ex-
pression patterns. Transcripts in modules 3,4,5 and 6 are downregulated and those in modules 1 and
2 are upregulated. The group on the left in Figure 3 (modules 1 and 2) contains many transcripts
involved in cell differentiation, neuron development, immune response, stress response, etc., while
the group on the right contains genes involved in negative regulation of metabolism, protein trans-
port, sodium ion transport, etc. Table 1 shows the top enriched GO biological processes (p < 0.05)
in all 6 modules.
As can be noted from Table 1, many processes linked to Alzheimer’s, such as immune response,
inflammatory response, cell development and differentiation (due to a large number of cancer
related genes), etc. are upregulated in incipient AD(Norris et al., 2005; Y et al., 2001). Processes
related to actin are downregulated in AD(Kojima and Shirao, 2007). Table 2 shows the most
significant KEGG pathways represented by the genes in each module. Although, there was no
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Figure 2: The adjacency matrix representation of the coexpression network. The graphical representation
of this matrix is in Figure 3. Modules are labelled c1, c2, c3, c4, c5 and c6. Modules c1 and c2 refer to the
group on the left in Figure 3 and the modules c3, c4, c5 and c6 refer to the one on the right. The dots refer
to the intra- and inter-module edges between the genes.
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Table 1: Top enriched GO biological processes in each module (p < 0.05)
Module Activity Ease score
Module 1 Protein biosynthesis 7.14E-06
Cell development 2.37E-05
Cell differentiation 4.88E-05
Macromolecule biosynthesis 8.56E-05
Cellular nerve ensheathment 1.11E-04
Neuron development 2.22E-04
Regulation of action potential 4.37E-04
Module 2 Response to other organism 0.004
Immune response 0.014
Defense response 0.020
Response to stress 0.029
Protein kinase cascade 0.030
Integrin-mediated signalling pathway 0.030
Myeloid cell differentiation 0.040
JAK-STAT cascade 0.042
Module 3 Homophilic cell adhesion 2.58E-11
Cell-cell adhesion 2.74E-09
Nervous system development 3.44E-09
Ion transport 0.007
Gamma-aminobutyric acid signalling pathway 0.009
Secretory pathway 0.019
Small gtpase mediated signal transduction 0.028
Sodium ion transport 0.036
Module 4 Cellular physiological process 6.91E-05
Transcription from RNA polymerase II promoter 0.008
Protein transport 0.014
Post-chaperonin tubulin folding pathway 0.019
Ubiquitin cycle 0.037
Module 5 Negative regulation of metabolism 0.011
Actin filament depolymerisation 0.025
Barbed-end actin filament capping 0.025
Negative regulation of actin filament depolymerisation 0.025
Negative regulation of protein metabolism 0.025
Module 6 Protein transport 0.008
Cell organisation and biogenesis 0.011
Membrane fusion 0.028
RNA processing 0.029
RNA splicing 0.042
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Table 2: Over-represented KEGG pathways in each module (p < 0.05).
Module KEGG pathway Ease score
Module 1 Ribosome 8.16E-07
Translation 3.41E-14
Module 2 Phospholipid degradation 0.013
Module 3 Signal transduction 0.002
Phosphatidylinositol signalling system 0.005
Module 4 Neuron development 2.22E-04
Module 6 Nucleotide metabolism 0.036
over-represented KEGG pathway in module 5, several genes involved in the negative regulation of
metabolism, actin filament depolymerisation, glucose metabolism, lipid biosynthesis were present.
Modules 2,3,4,5 and 6 represent processes previously associated to AD in multiple studies(Norris
et al., 2005; Y et al., 2001; Kojima and Shirao, 2007). Module 3,4,5 and 6 contain genes that
have decreased expression levels. In particular, module 5 contains processes related to glucose
metabolism. Recent work has shown decreased expression of energy metabolism genes(Liang
et al., 2008). Our results further confirm this observation. Based on the results obtained thus far,
each cluster/module can be a representative of some biological processes - module 1 represents
protein synthesis, module 2 is linked to phospholipid degradation, module 3 is associated with
signalling systems, module 4 represents neuron development and modules 5 and 6 are associated
with metabolism.
The modular organisation of genes led to the following investigative steps - (a) the identification
of module(s) associated with human diseases, (b) the identification of hub / highly connected genes
within the modules, (c) the examination of the expression level of brain derived neurotrophic factor
in the AD subjects, and (d) the identification of cis-regulatory elements from the promoters of
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genes.
This prompted an in-depth examination of module 1.
3.1.1 Module associated with cardiovascular diseases and diabetes
When EASE (http://niaid.abcc.ncifcrf.gov/home.jsp) was used to perform functional annotation
clustering based on the genes’ association to human disorders/diseases, module 1 was the only
module that had 18 disease associated genes (see Table 3). The connection to human condi-
tions and diseases was made by EASE using the Genetic Association Database (geneticassocia-
tiondb.nih.gov). Modules 2-6 did not have a significant enrichment for any human disease.
Table 3: Functional annotation clustering of genes in module 1 based on association to human
conditions/diseases
Disease/condition Genes
Neurodegeneration VWF, A2M, APOE, FTL, PON2, COMT, MAP4, TF, SERPINA3, ATP1A2, AGT
Myocardial infarction A2M, APOE, PON2, SERPINA3
Alzheimer’s disease A2M, APOE, SERPINA3, PON2
Cardiovascular VWF, A2M, APOE, PON2, COMT, WNK1, CBS, SERPINA3, TIMP1
Coronary artery disease APOE, PON2, COMT, SERPINA3
Type 2 Diabetes VWF, A2M, APOE, PCBD2, HLA-DQB1(HLA-DQB2), TIMP3, SLC2A1, AGT
These results provide a new set of evidence supporting the hypothesis that there may be a
strong association between cardiovascular disease (CVD) and the incidence of Alzheimer’s dis-
ease(STAMPFER, 2006; Rosendorff et al., 2007; STEWART, 1998). There also has been a grow-
ing body of evidence for a link between AD and diabetes(Janson et al., 2004; MacKnight et al.,
2002; Craft and Watson, 2004), with many research groups and news articles reporting that AD
may be another form of diabetes. While there are many shared transcripts in Table 3 among the
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different conditions, there are a few that are unique to the disease/condition, such as kinase defi-
cient protein (WNK1), timp metallopeptidase inhibitor 1 (TIMP1) and cystathionine-beta-synthase
(CBS) which are specific to CVD, and pterin-4 alpha-carbinolamine dehydratase/dimerization co-
factor of hepatocyte nuclear factor 1 alpha (tcf1) 2 (PCBD2), timp metallopeptidase inhibitor 3
(TIMP3), solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1) and ma-
jor histocompatibility complex, class ii, dq beta 1 (HLA-DQB1) being specific to diabetes. On
the other hand, von willebrand factor (VWF), alpha-2-macroglobulin (A2M), apolipoprotein e
(APOE), paraoxonase 2 (PON2), and serpin peptidase inhibitor, clade a (alpha-1 antiproteinase,
antitrypsin), member 3 (SERPINA3) are common to most of the conditions. This indicates that
genes that are specific to CVD and diabetes, conditions commonly associated with AD, were iden-
tified to be in the same module as genes related to neurodegenerative disease, including AD. Since
the motivation behind co-expression network analysis is to identify possibly co-regulated genes, it
is possible that these genes are co-regulated. Since genes that are common as well as those that
are specific to the conditions in Table 3 are being co-regulated, it may be the reason for the clus-
tering of these conditions in epidemiological studies. Furthermore, as there are many transcripts
common to these diseases/conditions, it is plausible that similar/common biochemical pathways
are active in these seemingly different conditions. If this is the case, then common pathogenetic
mechanisms for AD and CVD can suggest a causal link between CVD and AD(Rosendorff et al.,
2007; STEWART, 1998), a hypothesis that is still controversial and under a lot of debate.
Transcripts in the modules are linked to each other based on their expression similarity. ‘Hub
genes’ are highly-connected nodes/transcripts in the network and are likely to play important roles
in the biological processes. Hub genes tend to be conserved across species and hence, make excel-
lent candidates for disease association studies in humans(Casci, 2006).
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We defined hub genes to be those genes that have 40 or more links/connections. This re-
sulted in 107 hub genes. The complete list of hub genes, their module locations, and the num-
ber of links is in Supplemental Table S2. The hub genes included general transcription factor
iiic, polypeptide 1, alpha 220kda (GTF3C1) which is involved in RNA polymerase III-mediated
transcription, microtubule-associated protein 4 (MAP4) which promotes microtubule stability and
affects cell growth(Nguyen et al., 1998), and proprotein convertase subtilisin/kexin type 2 (PC2)
which is responsible for the processing of neuropeptide precursors. Some of these hub genes -
PC2, paraoxonase 2 (PON2) and peroxiredoxin 6 (PRDX6) - have been implicated in late-onset
AD (LOAD)(Krapfenbauer et al., 2003; Shi et al., 2004; Winsky-Sommerer et al., 2003).
Since module 1 has the disease associated genes, the identification of hub genes in this module
may provide new information regarding AD, CVD and diabetes. We identified 22 hub genes with
the number of links ranging from 42 to 63 in module 1 (For the complete list of 22 hub genes, see
Table S2). The total number of hub genes in each module along with the minimum and maximum
number of links is shown in Table 4.
Table 4: Number of hub genes and their range of connections/links in each module
Module No. hubs Range of links
Module 1 22 42 – 63
Module 2 17 41 – 56
Module 3 15 40 – 68
Module 4 14 40 – 65
Module 5 20 40 – 73
Module 6 19 40 – 81
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As shown in Table 4, module 1 had the maximum number of hub genes. The transcript with
the largest number of links in module 1 is MAP4 with 63 connections. Table 5 shows the number
of links for the 18 disease associated genes.
Table 5: Number of links of the 18 disease associated genes from module 1 and the number of
connections they have with other hub genes
Gene No. links No. hub genes it is connected to
VWF 16 2
A2M 17 3
APOE 18 3
FTL 18 3
PON2 51 8
COMT 17 0
MAP4 63 1
TF 16 3
SERPINA3 18 3
ATP1A2 45 6
AGT 27 5
TIMP1 14 2
WNK1 17 1
CBS 16 3
PCBD2 16 0
HLA-DQB1 15 2
SLC2A1 14 1
TIMP3 14 0
It can be seen from Table 5, that PON2, MAP4 and atpase Na+/K+ transporting, alpha 2
(+) polypeptide (ATP1A2) are hub genes. The overexpression of MAP4 results in the inhibi-
tion of organelle motility and trafficking(Bulinski et al., 1997) and can also lead to changes in cell
growth(Nguyen et al., 1998). ATP1A2 is a subunit of an integral membrane protein which is re-
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sponsible for establishing and maintaining the electrochemical gradients of Na and K ions across
the plasma membrane(Dennis et al., 2003). These gradients are essential for osmoregulation, for
sodium-coupled transport of a variety of molecules, and for electrical excitability of nerve and
muscle(Dennis et al., 2003). While the downregulation of ATP1A2 has been linked to migraine
related conditions(De Fusco et al., 2003), the effects of its upregulation has not been documented.
PON2 has been implicated in AD(Shi et al., 2004) and cardiovascular diseases (Table 3).
MAP4 is directly linked (linkage implies similarity in gene expression profile) to other dis-
ease/condition associated genes such as VWF and WNK1. Increased expression of semaphorin
3b (SEMA3B) (semaphorin pathway) inhibits axonal elongation(Blalock et al., 2004), which has
been implicated in AD(Blalock et al., 2004). MAP4 is also connected to SEMA3B. Many of the
18 disease associated genes are linked to one or more hub genes (see Table 5). Although, not all
the disease associated genes are hub genes themselves, most of them are directly linked to one or
more hub genes, which implies that they may play a role via hub genes in the biological processes
represented by the module.
3.1.2 Decreased levels of brain-derived neurotrophic factor
Brain-derived neurotrophic factor (BDNF) is well known for its trophic functions and has been im-
plicated in synaptic modulation, and the induction of long-term potentiation (LTP)(Yamada et al.,
2002; Tyler et al., 2002). Decreased levels of BDNF has been linked to Alzheimer’s and depres-
sion(Tsai, 2003; Laske et al., 2006; Karege et al., 2002). Recently, low levels of BDNF has also
been associated with diabetes(Krabbe et al., 2007).
BDNF goes through post-translational modification i.e. converted into mature BDNF by plas-
minogen (PLG) (http://www.genecards.org). The neurotrophic tyrosine kinase, receptor, type 2
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(NTRK2/TrkB) is a receptor for BDNF(Haapasalo et al., 2002).
BDNF was not present in our list of 1663 significant genes. However, TrkB and serpin pep-
tidase inhibitor, clade e (nexin, plasminogen activator inhibitor type 1), member 2 (SERPINE2)
were present in the set of 1663 genes and located in module 1. Plasminogen activator inhibitor
type 1 (PAI-1) proteins inhibit plasminogen (PLG) activators(Huber et al., 2001). Therefore, if
the level of PAI-1 is high in the AD affected samples, plasminogen activators are being inhibited,
resulting in decreased levels of mature BDNF. Interestingly, the expression levels of TrkB and
PAI-1 were elevated in the AD samples. However, TrkB is downregulated following the binding
of BDNF(Sommerfeld et al., 2000). Therefore, due to an increased level of PAI-1, mature BDNF
could not be produced, which in turn could not bind to TrkB. Hence, from this analysis it can be
concluded that high levels of TrkB and PAI-1 implies decreased levels of BDNF, which is very crit-
ical for the survival of neuronal populations. This probably leads to neuronal death in this cohort
of AD affected subjects.
In order to verify our conclusion regarding the expression level of BDNF in the AD patients in
our dataset, we examined the expression level of BDNF in the controls and AD affected samples.
We found BDNF to be decreased by 1.07 in the AD affected samples. BDNF was not selected to
be a significant gene probably because it had a small difference in the expression between controls
and affected samples. Microarrays are not sensitive enough to detect genes with low expression
levels, especially when the difference in expression is small (which can be expected in subjects
with incipient AD)(Bunney et al., 2003; Pan et al., 2006; Yue et al., 2001; Canales et al., 2006).
The fact that the selected significant genes, such as TrkB and SERPINE2, could lead to the correct
conclusion regarding the level of BDNF expression in AD affected samples, highlights the merits
of this kind of analysis of the transcriptome when handling genes with low expression levels.
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Although modules 1 and 2 have upregulated genes, genes associated with BDNF are located only
in module 1. This further emphasises the importance of module 1.
3.1.3 Comparison to the study by Miller et al. on ageing and AD
Miller et al. identified 558 transcripts that were common to AD and ageing(Miller et al., 2008).
We found more overlapping genes between our study and their’s than expected by chance (p = 3.3
X 10−10). 94 genes overlapped between 1663 significant genes from our study and 558 genes
identified by Miller et al.. Of these 94 genes, 48 were present in module 1 (greater than expected
by chance p = 9.2X 10−10), while the overlap between 558 AD-ageing genes and genes in modules
2,3,4,5 and 6 ranged between 2 - 15. This indicates that module 1 contains the majority of genes
that have been linked to ageing and AD. Of the 48 genes that overlapped between 558 AD-ageing
common genes and genes in module 1, WNK1 and MAP4 were present. MAP4 is associated with
neurodegeneration while WNK1 is linked to cardiovascular diseases.
Furthermore, 9 genes (DAAM2, EPM2AIP1, GFAP, GORASP2, MAP4, NFKBIA, PRDX6,
TSC22D4 and UBE2D2) overlapped between 558 AD-ageing genes and the 107 hub genes identi-
fied in our study, 5 of which resided in module 1. These results further emphasise the significance
of module 1. From these results, it can be concluded that module 1 is an important link in the chain
of pathophysiological characteristics connecting AD, CVD and ageing. It represents common bio-
chemical pathways that may be affected in all these conditions.
3.2 Cis-regulatory elements and co-regulated genes
Cis-regulatory elements/motifs are regulatory elements in the promoter region of genes to which
transcription factors (TFs) bind, and regulate transcription. If a group of genes share the same
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cis-regulatory motif, then the TF that binds to the motif may regulate this group of genes. Co-
expressed modules represent genes that may be co-expressed in the cell and be a part of the same
biochemical pathways. Throughout the results in section 3.1 of our analysis, we observe that the
genes contained in module 1 is of high importance. Since module 1 is the most important module
identified in this analysis, we attempted to identify the cis-regulatory elements/motifs that may be
enriched in the upstream promoter sequences of the genes in module 1. The group of genes in
module 1 that share a motif will be a set that is co-expressed and co-regulated.
The complete set of cis-regulatory elements enriched in module 1 is in Supplemental Table S3.
A total of 89 motifs were specifically enriched in module 1 with a p-value < 0.001, and their target
genes were co-expressed with an average correlation coefficient > 0.4 and Z-score > 2 (see Data
and Methods). Of the 89 motifs, 36 matched to 26 known transcription factor binding sites (TFBS)
in JASPAR (http://jaspar.genereg.net/) with a matching score ≥ 0.8 (see Table 6). Table 6 shows
the number of genes within module 1 whose promoter region contains a motif that matched to the
TFBS of a known TF.
Transcription factors such as growth factor independent (Gfi), peroxiredoxin 2 (Prx2/PRDX2),
SP1, CAAT-enhancer binding protein C/EBP), RelA(p65), runt box 1 (Runx1), ELK-1, upstream
stimulatory factor 1 (USF1), Rel, TATA box binding protein (TBP) have been implicated in neu-
rodegenerative diseases (such as AD, Parkinson’s, and Schizophrenia)(Tsuda et al., 2005; Qu et al.,
2007; Fang et al., 2007; Santpere et al., 2006; Christensen et al., 2004; Li et al., 2004; Perez-Capote
et al., 2006; Barkett and Gilmore, 1999; Tomita et al., 2000; Kimura et al., 2007; Pastorcic and Das,
2003; Tong et al., 2004; Salero et al., 2003; Reid et al., 2004), diabetes(Ng et al., 2005), stroke and
cardiovascular diseases(Choquette et al., 2007; Komulainen et al., 2006). 139 genes in module 1
contained motifs that matched the TFBS of the known TFs associated with these diseases.
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Table 6: The 26 known TFs and the number of target genes in module 1 that have a motif in their
promoters that match to the binding sites of the known TF
26 Transcription factors No. target genes
ABI4 9
Arnt-Ahr 93
ARR10 6
Broad-complex 3 10
cEBP 20
Gfi 8
HAND1-TCF3 279
Mycn 11
Myf 8
Prx2/PRDX2 17
RELA, REL 10
RUNX1 4
Snail 49
SP1 47
TBP 6
E74A 16
ELK1 16
SPIB 16
Hunchback 6
MAX 11
USF1 11
ZNF42 5–13 27
NFIL3 5
Agamous 8
GAMYB 6
Arnt-Ahr dimer transcription factor activates genes crucial in the response to hypoxia and hy-
poglycaemia(Maltepe et al., 1997; Erbel et al., 2003). Hypoglycaemia and hypoxia have been
known to play pathophysiological roles in the complications of diabetes and AD(Catrina et al.,
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2004; Shi et al., 1997; Peers et al., 2007; Sun et al., 2006). It is well known that hypoxia has major
effects on the cardiovascular system(Germack et al., 2002). Therefore, in light of such knowledge,
it is no surprise that a large number of genes have cis-regulatory motifs that match the binding site
of the Arnt-Ahr TF.
Hand1-TCF3 and TAL1-TCF3 are components of the basic-helix-loop-helix (bHLH) com-
plexes. BHLH transcription factors are important in development (Yelon et al., 2000; Firulli et al.,
2003). An extremely high number of genes were mapped to Hand1-TCF3 since cell development
and differentiation is upregulated in AD (Norris et al., 2005; Y et al., 2001).
In summary, the fact that TFs which are active in other human diseases/disorders have their
binding motifs enriched in the set of significant genes associated with AD adds significance to the
hypothesis that many common biochemical pathways are affected in AD and CVD.
4 Conclusion
In this study, we presented an integrative systems biology approach to study a complex disease
such as Alzheimer’s disease. Along with identifying modules / clusters that illuminate higher-
order properties of the transcriptome, we identified a module that contained many genes known
to play prominent roles in cardiovascular diseases and AD. We identified several cis-regulatory
elements, some of which mapped to the binding sites of known TFs involved in neurodegenerative
and cardiovascular diseases as well as diabetes and stroke. Furthermore, since microarrays are
not sensitive to genes with very slight differences in expression from controls, we illustrated how
other genes can be used to deduce the expression difference of such genes. This is especially
critical while comparing groups that are very similar to each other.
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The link between cardiovascular diseases, diabetes and AD is a topic of growing interest. The
presence of genes and cis-regulatory elements related to cardiovascular diseases and AD in a single
module, provides strong evidence to the hypotheses connecting these two conditions. Interestingly,
this module also contained the maximum number of genes (and hub genes) related to ageing. Our
results support the notion that diseases in which the same set of biochemical pathways are affected
may tend to co-occur with each other. This may be the reason why cardiovascular diseases and/or
diabetes co-occur with AD. A comprehensive analysis incorporating AD and CVD/diabates pa-
tients along with information about their disease progression will lead to a more powerful analysis.
Such a study will shed more light into the pathophysiology of AD and associated diseases.
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Figure 3: Co-expression network with 6 modules. A node refers to a gene and the weight of an edge is the
Pearson correlation coefficient between expression profiles of a pair of genes scaled to within [0,1]. The 2
large groups are two sets of genes with anti-correlated expression patterns. The group on the left contain
all upregulated genes and the group on the right consist of downregulated genes. The length of each edge
and the position of each node/module does not have any biological meaning and are arbitrarily chosen for
proper visualisation. Best viewed in colour.
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